Sandoz Neulasta biosimilar rejected by FDA

21-07-2016

The US Food and Drug Administration (FDA) has given Sandoz a complete response to its Neulasta (pegfilgrastimcandidate) biosimilar application, in which the application was rejected.


Sandoz, Neulasta, biosimilar, Novartis, FDA

LSIPR